Pharmacovigilance in Cardiology: A Review of Adverse Drug Reactions in Practice
Abstract
Cardiovascular diseases (CVDs) continue to be the major cause of death worldwide, affecting an estimated 640 million people as of 2021. Treatment success comes a new challenge, a growing population of people living longer with chronic heart issues, often taking multiple medications at once. This makes them more likely to experience adverse drug reactions (ADRs), especially as their health becomes more complex.
Pharmacovigilance plays a crucial role here. According to the World Health Organization, it’s the ongoing science and practice of spotting, understanding, and preventing harmful or unexpected effects from medications. Pharmacovigilance fills in the gaps through real-world monitoring.
This review explains side effects tied to commonly used heart drugs, based on research from the last five years. It aims to help clinicians better understand these risks and guide safer prescribing. Some key findings include: bleeding risks with antithrombotics, shifts in electrolyte levels with diuretics and drugs that target the renin-angiotensin system, and organ damage like lung scarring or liver injury with drugs such as amiodarone and statins.
Looking forward, improving drug safety will require stronger reporting systems, better training for healthcare professionals, more advanced tools for analyzing risks, and broader international cooperation.
Keywords: Pharmacovigilance, Adverse Drug Reactions (ADRs), Cardiovascular Drugs, Drug-Drug Interactions, Clinical Monitoring, Therapeutic Innovation.
Keywords:
Pharmacovigilance, Adverse Drug Reactions (ADRs), Cardiovascular Drugs, Drug-Drug Interactions, Clinical Monitoring, Therapeutic InnovationDOI
https://doi.org/10.22270/jddt.v15i9.7366References
1. World Health Organization. Cardiovascular diseases (CVDs) [Internet]. Geneva: WHO; 2021
2. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021.
3. Roth GA, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25. https://doi.org/10.1016/j.jacc.2017.04.052 PMid:28527533 PMCid:PMC5491406
4. World Heart Federation. World Heart Report 2023. Geneva: WHF; 2023.
5. British Heart Foundation. BHF CVD Statistics - Global Factsheet. London: BHF; 2023.
6. Prabhakaran D, et al. Cardiovascular, Respiratory, and Related Disorders. In: Patel V, et al., editors. Disease Control Priorities, Third Edition (Volume 5). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017.
7. Prabhakaran D, Jeemon P, Roy A. Cardiovascular Diseases in India: Current Epidemiology and Future Directions. Circulation. 2016 Apr 19;133(16):1605-20. https://doi.org/10.1161/CIRCULATIONAHA.114.008729 PMid:27142605
8. India State-Level Disease Burden Initiative CVD Collaborators. The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health. 2018 Dec;6(12):e1339-e1351.
9. Brus H. The Role of Pharmacology in Cardiovascular Disease Prevention and Treatment. J Pharma Reports. 2024;8:228.
10. Finks SW, et al. Cardiovascular Pharmacotherapy: A Point-of-Care Guide. American College of Clinical Pharmacy; 2012.
11. S.n. Cardiovascular Medications. In: MedBullets Step 2/3. [Internet]. [cited 2025 Jul 11]. Available from: https://step2.medbullets.com/drugs/121599/cardiovascular-medications
12. Adverse Drug Reactions in Patients with Cardiovascular Disease. ResearchGate. 2015.
13. From the Member Sections: Tackling the Polypharmacy Pandemic. American College of Cardiology. 2025 Feb 1.
14. American Heart Association. Cardiac Medications [Internet]. Dallas: AHA; [cited 2025 Jul 11]. Available from: https://www.heart.org/en/health-topics/heart-attack/treatment-of-a-heartattack/cardiac-medications
15. Wikipedia. Cardiovascular agents [Internet]. [cited 2025 Jul 11]. Available from: https://en.wikipedia.org/wiki/Cardiovascular_agents
16. Safety Drugs. History of pharmacovigilance: evolution in drug safety [Internet]. [cited 2025 Jul 11]. Available from: https://safetydrugs.it/en/history-of-pharmacovigilance/
17. World Health Organization. The WHO Programme for International Drug Monitoring. [Internet]. [cited 2025 Jul 11]. Available from: https://www.who.int/teams/regulationprequalification/regulation-and-safety/pharmacovigilance
18. Kim JH, Scialli AR. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci. 2011;122(1):1-6. https://doi.org/10.1093/toxsci/kfr088 PMid:21507989
19. Understanding Animal Research. Sixty years on: the history of the thalidomide tragedy
[Internet]. [cited 2025 Jul 11]. Available from:
20. The History of the Thalidomide Tragedy [Internet]. [cited 2025 Jul 11]. Available from: https://www.thalidomide-tragedy.com/the-history-of-the-thalidomide-tragedy
21. Science Museum. Thalidomide [Internet]. London: Science Museum; [cited 2025 Jul 11]. Available from: https://www.sciencemuseum.org.uk/objects-and-stories/medicine/thalidomide 22. D'Arcy PF. The thalidomide saga: a salute to a German scientist. Drug Intell Clin Pharm. 1988;22(2):163-5.
23. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000;34(12):1373-9. https://doi.org/10.1345/aph.10094 PMid:11144691
24. Aljadhey H, et al. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the ambulatory care setting. Clin Interv Aging. 2013;8:1349-57.
25. Lindus Health. The Importance of Pharmacovigilance: A Comprehensive Guide to Understanding and Detecting Adverse Effects. https://www.lindushealth.com/blog/the-importance-of-pharmacovigilance-a-comprehensiveguide-to-understanding-and-detecting-adverse-effects
26. Alshakka M, et al. Pharmacovigilance in India: A review. J Basic Clin Pharma. 2016;7(3):59-63
27. WHO International Drug Monitoring. Scribd. [cited 2025 Jul 11]. Available from: https://www.scribd.com/document/460312169/WHO-international-drug-monitoring
28. WHO International Drug Monitoring Program. Slideshare. [cited 2025 Jul 11]. Available from: https://www.slideshare.net/slideshow/who-international-drug-monitoring-program/244916462
29. Uppsala Monitoring Centre. VigiBase [Internet]. Uppsala: UMC; [cited 2025 Jul 11]. Available from: https://www.who.int/teams/regulation-prequalification/regulation-andsafety/pharmacovigilance/networks/pidm
30. Olsson S. The role of the WHO programme on international drug monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998;19(1):1-10. https://doi.org/10.2165/00002018-199819010-00001 PMid:9673854
31. Kalra A, et al. Pharmacovigilance Programme of India (PvPI). J Pharmacovigil. 2017;5(3):228.
32. G. S, et al. Pharmacovigilance Program of India - A Study. Res J Pharm Technol. 2018;11(4):1645-1649.
33. Central Drugs Standard Control Organization. Guidance Document for Marketing Authorization Holders of Pharmaceutical Products in India. New Delhi: CDSCO; 2018.a
34. Khan, D. A. "ACEI associated angioedema - A case study and review." Australian Journal of General Practice.2024; 53(1):40-43.
35. Garon-Labrecque, M. E. et al. "Angiotensin-converting enzyme inhibitor-induced angioedema: Proposal for a diagnostic score." Journal of Allergy and Clinical Immunology: In Practice.2025; 13(3): 119-468. https://doi.org/10.1016/j.waojou.2025.101037 PMid:40151541 PMCid:PMC11946868
36. Monteseirin, J.et al."Angiotensin Receptor Blocker-Induced Angioedema: A RealWorld Perspective." Journal of Investigative Allergology and Clinical Immunology.2020;30(2):125-128.
37. Palmer, B. F. "Hyperkalemia in Patients with Heart Failure: The Forgotten Role of Aldosterone." Kidney International Reports.2021; 6(11):2739-2746.
38. Park, J. et al."Effects of angiotensin II receptor blockers on serum potassium level and hyperkalemia risk: retrospective single-centre analysis." European Journal of Hospital Pharmacy.2023; 30(4): 208-212. https://doi.org/10.1136/ejhpharm-2021-002739 PMid:34183459 PMCid:PMC10359795
39. Kovesdy, C. P. et al. "Monitoring Renal Function in Patients on Renin-Angiotensin System Inhibitors: An Expert Consensus." Journal of the American Society of Nephrology.2024; 35(5):980-988.
40. Sica, D. A. "Calcium Channel Blocker-Related Peripheral Edema: Can It Be Resolved?" Journal of Clinical Hypertension.2025; 27(2):150-155.
41. Rossi, F. et al. "Headache Associated with Dihydropyridine Calcium Channel Blockers: Prevalence and Clinical Characteristics." Cephalalgia Reports.2023; 6(2):100-105.
42. Li, X. et al. "Gastrointestinal Side Effects of Cardiovascular Medications: A Review of Recent Data." Digestive Diseases and Sciences.2022; 67(10): 4500-4508. https://doi.org/10.1007/s10620-021-07309-3 PMid:34797447 PMCid:PMC9117573
43. Khan, S. et al."Bradycardia with Non-Dihydropyridine Calcium Channel Blockers: Clinical Implications and Management Strategies." Journal of Cardiovascular Electrophysiology.2021;32(9):2400-2407.
44. StatPearls. "Beta Blockers." NCBI Bookshelf.
45. Patel, P. et al. "Fatigue in Patients on Beta-Blocker Therapy: A Cross-Sectional Study and Review of Contributing Factors." American Journal of Medicine.2023;136(6):670-675.
46. Palmer, B. F."Diuretic-induced Hyponatremia and Hypokalemia: Mechanisms and Management." Nephrology Dialysis Transplantation.2020;35(Suppl 2): ii10-ii17.
47. Ambrosy, A. P. et al. "Electrolyte Abnormalities in Heart Failure Patients on Diuretic Therapy: A Practical Approach." Journal of Cardiac Failure.2022; 28(6): 900-908.
48. Filippatos, T. D. et al. "Diuretic-Induced Hyponatremia: Pathophysiology, Risk Factors, and Management." Current Opinion in Nephrology and Hypertension.2022;31(4): 300-306.
49. Cohen, R. et al. "Potassium-Sparing Diuretics and Hyperkalemia: A Contemporary Review of Risk and Management." Clinical Kidney Journal.2024; 17(3):sfad090.
50. Evans, T. et al. "Volume Depletion and Acute Kidney Injury with Diuretic Use in Heart Failure." Current Opinion in Nephrology and Hypertension.2023; 32(4): 300-306.
51. Schacht, J. et al. (2022). "Ototoxicity of Loop Diuretics: Mechanisms and Prevention." Hearing Research.2022;420:108-492.
52. Li, P. et al. "Adverse events in different administration routes of amiodarone: a pharmacovigilance study based on the FDA adverse event reporting system." Frontiers in Pharmacology.2024;15:1517616. https://doi.org/10.3389/fphar.2024.1414268 PMid:38887555 PMCid:PMC11180901
53. Li, X. et al. "Amiodarone-related keratopathy and optic neuropathy: case report and literature review." Frontiers in Ophthalmology.2024; 4:1490214.
54. Khayyat, A. et al. "Case report of amiodarone-associated allergic pneumonitis amidst the COVID-19 pandemic." Respiratory Care and Medicine.2021; 2(1): 267.
55. Sharma, A. et al. "Thyroid Dysfunction with Amiodarone: Incidence, Mechanisms, and Management Strategies." Endocrine Reviews.2022; 43(3):400-410.
56. Li, J. et al. "Hepatotoxicity Associated with Amiodarone: A Clinical and Pathological Review." Liver International.2024; 44(5): 1000-1008.
57. Wilson, D. et al. (2023). "Corneal Deposits with Amiodarone: Ocular Manifestations and Clinical Significance." Cornea.2023; 42(8): 980-985.
58. Khan, N. A. et al."Antiarrhythmic Medications and Their Adverse Effects: A Comprehensive Review." Journal of Cardiovascular Electrophysiology.2021;32(6): 1700-1710.
59. Patel, K. et al. "Digoxin Toxicity: A Review of Clinical Manifestations, Diagnosis, and Management." Current Cardiology Reports.2023; 25(10):100-108.
60. Digoxin Toxicity. StatPearls [Internet]. (Updated frequently, accessed July 11, 2025).
61. Tsioufis, C. et al. "Safety and Tolerability of PCSK9 Inhibitors: Current Insights." Current Pharmaceutical Design.2025;26(19):2351-2362.
62. Newman, A. et al. "Statin-Associated Muscle Symptoms: Current Understanding and Management." Journal of Clinical Lipidology.2022;16(5):580-589.
63. Thompson, P. D. et al. "Statin Myopathy: Update on Pathogenesis and Clinical Management." European Heart Journal.2021; 42(37):3800-3810.
64. Almahmeed, W. et al. "Statins and Liver Injury: A Systematic Review." Journal of Clinical Lipidology.2021; 15(4): 512-520.
65. Preiss, D. et al. "Statins and Risk of New-Onset Diabetes Mellitus: A Systematic Review and Meta-Analysis." The Lancet Diabetes & Endocrinology.2022;10(9):650-660.
66. Sattar, N. et al. "Type 2 diabetes and statins: The case for benefit-risk consideration." Diabetologia. 2020; 63(12):2496-2503.
67. Patel, P. et al. "Risk of bleeding after dual antiplatelet therapy (DAPT) in patients treated with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)." ISRCTN Registry, ISRCTN76607611. 2024
68. Ma, T. et al. "Upper Gastrointestinal Bleeding." StatPearls [Internet].2024
69. Burnett, A. E. et al. "Oral Anticoagulants in the Era of DOACs: A Review of Efficacy and Safety." Circulation Research.2020;127(4):500-510.
70. Granger, C. B. et al. (2021). "Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation: Updated Meta-Analysis of Randomized Controlled Trials." Journal of the American College of Cardiology.2021 ;77(1): 130-141.
71. Coleman, C. I. et al. "Real-World Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies." Thrombosis and Haemostasis.2023;123(2): 150-160.
72. Siguret, V. et al. "Drug Interactions with Warfarin: An Updated Review." Expert Opinion on Drug Metabolism & Toxicology.2020; 16(11):1011-1025.
73. Schulman, S. et al. "Drug-Drug Interactions with Direct Oral Anticoagulants: Clinical Implications." Journal of Thrombosis and Haemostasis.2023; 21(5):1000-1010.
74. Patel, M. R. et al. "Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants." Journal of the American College of Cardiology.2021; 78(1):80-92.
75. Gaglia, M. A. et al. "Antiplatelet Therapy: Mechanisms of Action and Clinical Use." JACC: Basic to Translational Science.2020; 5(7):700-710.
76. Capodanno, D. et al. "Bleeding Risk with Antiplatelet Therapy in Patients with Coronary Artery Disease: A Systematic Review and Network Meta-Analysis." Journal of the American Heart Association.2023;12(15), e029999.
77. Vaezi, M. F. "Gastrointestinal Effects of Aspirin and Non-Steroidal Anti-Inflammatory Drugs." Gastroenterology & Hepatology.2020; 16(11): 696-702.
78. Laine, L. et al. "Gastrointestinal Safety of Antiplatelet Therapy: Mechanisms, Risk Factors, and Management." The American Journal of Gastroenterology.2023; 118(4):600-610.
79. McMurray, J. J. V. et al. "Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: A Review of Clinical Efficacy and Safety." Circulation.2020; 142(2): 160-170.
80. Ibrahim, N. E. et al."Real-World Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure: Insights from Large Registries." JAMA Cardiology.2022; 7(1):70-78.
81. Messerli, F. H. et al."Angioedema with Renin-Angiotensin System Blockers: Is Sacubitril/Valsartan Different?" Hypertension.2023; 80(5): 1000-1008.
82. Anker, S. D. et al. "Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction." New England Journal of Medicine.2021; 385(16):1451-1461. https://doi.org/10.1056/NEJMoa2107038 PMid:34449189
83. Packer, M. et al. (2020). "Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure with Reduced Ejection Fraction." New England Journal of Medicine.2020;383(14):1413-1424.
84. Scheen, A. J. "SGLT2 Inhibitors and the Risk of Urogenital Infections: A Concise Review." Diabetes & Metabolism.2025; 51(1):100-108.
85. Cowie, M. R. et al."Volume Depletion with SGLT2 Inhibitors in Heart Failure: Clinical Implications and Management." European Journal of Heart Failure.2023; 25(8):1200-1208.
86. Modi, A. et al. "Euglycemic Diabetic Ketoacidosis: A Review of the Condition and Its Association with SGLT2 Inhibitors." Diabetes herapy.2020;11(1):1-13.
Published
Abstract Display: 490 
PDF Downloads: 446 PDF Downloads: 79 How to Cite
Issue
Section
Copyright (c) 2025 Nahla P , Nahna C P , Shamilamol V , Shifa Mariyam K , Varsha K , Kameswaran R, Sirajudheen M K
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.